Effect of Transgenic Expression of Human Decay—Accelerating Factor on the Inhibition of Hyperacute Rejection of Pig Organs

  • E. Cozzi
  • N. Yannoutsos
  • G. A. Langford
  • G. Pino-Chavez
  • J. Wallwork
  • D. J. G. White
Chapter

Abstract

Clinical xenotransplantation utilizing pig organs represents, in theory, a very attractive solution to the worldwide shortage of organs for human transplantation. The use of pigs as organ donors has several advantages over the choice of any other species [1]. The pig has a short gestation period, it produces large litters and its offspring grow very rapidly. Utilization of pigs would also eliminate the ethical and virological concerns associated with the use of organs from nonhuman primates [2]. However, hyperacute rejection (HAR), which occurs when transplanting between discordant xeno combinations, currently represents the major immunological barrier to the survival of pig organs into primates [3–5]. The binding of naturally occurring cytotoxic xenoreactive antibodies (XNA) mainly directed to the carbohydrate structure Galα1-3Galß1-4GlcNAc-R [6–8] on porcine endothelial cells and the activation of the recipient’s complement cascade represent the sequence of immunological events which underlie HAR [5, 9, 10].

Keywords

Cynomolgus Monkey Yeast Artificial Chromosome Human Complement Membrane Cofactor Protein Hyperacute Rejection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooper DKC, Ye Y, Rolff LL, Zuhdi N. The pig as potential organ donor for man. In: Xenotransplantation, (First edition). Cooper DKC, et al. (eds). Heidelberg, Springer, 1991, p. 481Google Scholar
  2. 2.
    Allan JS. Xenotransplantation at a crossroads: Prevention versus progress. Nature Med 1996; 2: 18PubMedCrossRefGoogle Scholar
  3. 3.
    Dalmasso AP, Vercellotti GM, Fischel RJ, et al. Mechanisms of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140(5): 1157PubMedGoogle Scholar
  4. 4.
    Zhao Z, Termignon JL, Cardoso J, et al. Hyperacute xenograft rejection in the swine to-human donor-recipient combination. In vitro analysis of complement activation. Transplantation 1994; 57: 245PubMedCrossRefGoogle Scholar
  5. 5.
    Piatt JL, Bach FH. The barrier to xenotransplantation. Transplantation 1991; 52: 937CrossRefGoogle Scholar
  6. 6.
    Good AH, Cooper DKC, Malcolm AJ, et al. Identification of carbohydrate structures which bind human anti-porcine antibodies: implications for discordant xenografting in man. Transplant Proc 1992; 24: 559PubMedGoogle Scholar
  7. 7.
    Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α1–3)Gal epitopes. Proc Natl Acad Sci 1993; 90: 11391PubMedCrossRefGoogle Scholar
  8. 8.
    Galili U. Interaction of the natural anti—Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480PubMedCrossRefGoogle Scholar
  9. 9.
    Bach FH, Blakely ML, Van Der Werf M, et al. Discordant xenografting: a working model of problems and issues. Xeno 1993; 1: 8Google Scholar
  10. 10.
    Auchincloss H Jr. Xenogeneic transplantation: a review. Transplantation 1988; 46: 1PubMedCrossRefGoogle Scholar
  11. 11.
    Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964PubMedCrossRefGoogle Scholar
  12. 12.
    Oriol R, Ye Y, Koren E, Cooper DKC. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433PubMedCrossRefGoogle Scholar
  13. 13.
    d’Apice AJF, Tange MJ, Chen C-G, et al. Gal(α1,3)Gal: elimination, suppression, masking or none of the above? Xeno 1995; 3: 113Google Scholar
  14. 14.
    Koike C, Hayashi S, Yokoyama I, et al. Converting α-Gal epitope of pig into H antigen. Transplant Proc 1996; 28: 553PubMedGoogle Scholar
  15. 15.
    Makowka L, Cramer DV, Hoffman A, et al. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure. Transplantation 1995; 59: 1654CrossRefGoogle Scholar
  16. 16.
    Busch GJ, Martins ACP, Hollenberg NK, Wilson RE, Colman RW. A primate model of hyperacute renal allograft rejection. Am J Pathol 1975; 79: 31PubMedGoogle Scholar
  17. 17.
    Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825PubMedCrossRefGoogle Scholar
  18. 18.
    Chartrand C, O’Regan S, Robitaille P, Pinto-Blonde M. Delayed rejection of cardiac xenografts in C6-deficient rabbits. Immunology 1979; 38: 245PubMedGoogle Scholar
  19. 19.
    Brauer RB, Baldwin WM, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant xenografts. J Immunol 1993; 151: 7240PubMedGoogle Scholar
  20. 20.
    Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857PubMedCrossRefGoogle Scholar
  21. 21.
    Johnston PS, Lim SML, Wang MW, Wright L, White DJG. Hyperacute rejection of xenografts in the complete absence of antibody. Transplant Proc 1991; 23: 877PubMedGoogle Scholar
  22. 22.
    Pruitt SK, Kirk DA, Bollinger RR, et al. The effect of soluble complement receptor type1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363PubMedCrossRefGoogle Scholar
  23. 23.
    Kobayashi T, Neethling FA, Koren E, et al. In vitro and in vivo investigation of anticomplement agents, FUT-175 and K76COOH, in the prevention of hyperacute rejection following discordant xenotransplantation in a nonhuman primate model. Transplant Proc 1996; 28: 604PubMedGoogle Scholar
  24. 24.
    Kroshus TJ, Rollins SA, Dalmasso AP, et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1995; 60: 1194PubMedGoogle Scholar
  25. 25.
    Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation 1995; 60: 1282Google Scholar
  26. 26.
    Lachmann PJ. The control of homologous lysis. Immunol Today 1991; 12: 312PubMedCrossRefGoogle Scholar
  27. 27.
    Morgan BP, Meri S. Membrane proteins that protect against complement lysis. In: Springer Seminars in Immunopathology.Heidelberg, Springer, 1994, p. 369Google Scholar
  28. 28.
    Wang M-W, Wright LJ, Sims MJ, White DJG. Presence of human chromosome 1 with expression of human decay— accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement. Scand J Immunol 1991; 34: 771PubMedCrossRefGoogle Scholar
  29. 29.
    White DJG, Oglesby TJ, Tedja I, et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl Int 1992; 5: 648Google Scholar
  30. 30.
    Lewin B. Organization of the eukaryotic genome. In: Genes V. Lewin B (ed). Oxford, Oxford University Press, 1994Google Scholar
  31. 31.
    Miller JFAP. Application of molecular genetics to transplantation immunology. Trans-plant Proc 1991; 23: 1717Google Scholar
  32. 32.
    Grosveld F, Blom van Assendelft G, Greaves DR, Kollias G. Position-independent, high-level expression of the human ß-globin gene in transgenic mice. Cell 1987; 51: 975PubMedCrossRefGoogle Scholar
  33. 33.
    Grosveld F, Antoniou M, Berry M, et al. Regulation of human globin gene switching. In: Cold Spring Harbor Symposia on Quantitative Biology, volume 58, 7. Cold Spring Harbor Laboratory Press, 1993Google Scholar
  34. 34.
    Pinkert CA. Transgenic pig models for xenotransplantation. Xeno 1994; 2: 10Google Scholar
  35. 35.
    Post TW, Arce MA, Liszewski MK, et al. Structure of the gene for human complement protein decay accelerating factor. J Immunol 1990; 144: 740PubMedGoogle Scholar
  36. 36.
    Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9: 431PubMedCrossRefGoogle Scholar
  37. 37.
    Tone M, Walsh LA, Waldmann H. Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. J Mol Biol 1992; 227: 971PubMedCrossRefGoogle Scholar
  38. 38.
    Vize PD, Michalska AE, Ashman R, et al. Introduction of a porcine growth hormone fusion gene into transgenic pigs promotes growth. J Cell Sci 1988; 90: 295PubMedGoogle Scholar
  39. 39.
    Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci 1988; 85: 836PubMedCrossRefGoogle Scholar
  40. 40.
    Pursel VG, Bolt DJ, Miller KF, et al. Expression and performance of transgenic pigs. J Reprod Fertil 1990; 40: 235Google Scholar
  41. 41.
    Post TW, Liszewski MK, Adams ME, et al. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 1991; 174: 93PubMedCrossRefGoogle Scholar
  42. 42.
    Russell SM, Sparrow RI, McKenzie IFC, Purcell DFJ. Tissue-specific and allelic expression of CD46 is controlled at the level of alternative splicing. Eur J Immunol 1992; 22: 1513PubMedCrossRefGoogle Scholar
  43. 43.
    Burke DT, Olson MV. Preparation of clone libraries in yeast artificial chromosome vectors. Methods Enzymol 1991; 194: 251PubMedCrossRefGoogle Scholar
  44. 44.
    Ioannou PA, Amemiya CT, Games J, et al. A new bacteriophage Piderived vector for the propagation of large human DNA fragments. Nature Genetics 1994; 6: 84PubMedCrossRefGoogle Scholar
  45. 45.
    Yannoutsos N, Ijzermans JNM, White D, Grosveld F. Using yeast artificial chromosomes to generate transgenic animals. Xeno 1995; 3: 107Google Scholar
  46. 46.
    Hammer RE, Pursel VG, Rexroad CE, et al. Production of transgenic rabbits, sheep and pigs by microinjection. Nature 1985; 315: 680PubMedCrossRefGoogle Scholar
  47. 47.
    Cozzi E, Langford GA, Richards A, et al. Expression of human decay accelerating factor in transgenic pigs. Transplant Proc 1994; 26: 1402PubMedGoogle Scholar
  48. 48.
    White DJG, Langford GA, Cozzi E, Young VJ. Production of pigs transgenic for human DAF. A strategy for xenotransplantation. Xenotransplantation 1995; 2: 213.CrossRefGoogle Scholar
  49. 49.
    Ono K, Lindsay L. Improved technique of heart transplantation in the rat. J Thorac Cardiovasc Surg 1969; 57: 225PubMedGoogle Scholar
  50. 50.
    Piatt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH. Endothelial cell antigens recognized by xenoreactive human natural antibodies. Transplantation 1990; 50: 817CrossRefGoogle Scholar
  51. 51.
    Van den Bogaerde JB, Aspinall R, Wang M-W, et al. Induction of long-term survival of hamster heart xenografts in rats. Transplantation 1991; 52: 15PubMedCrossRefGoogle Scholar
  52. 52.
    Platt JL, Holzknecht ZE. Porcine platelet antigens recognized by human xenoreactive natural antibodies. Transplantation 1994; 57: 327PubMedCrossRefGoogle Scholar
  53. 53.
    van den Berg CW, Morgan BP. Complement-inhibiting activities of human CD59 and analogues from rat, sheep and pig are not homologously restricted. J Immunol 1995; 152: 4095Google Scholar
  54. 54.
    Euler HH, Schroder OJ, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmaphersis with subsequent pulse cyclophosphamide. Arthritis Rheumatism 1994; 12: 1784CrossRefGoogle Scholar
  55. 55.
    Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741PubMedCrossRefGoogle Scholar
  56. 56.
    McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423PubMedCrossRefGoogle Scholar
  57. 57.
    Alexandre GPJ, Gianello P, Latinne D, et al. Plasmaphersis and splenectomy in experimental renal xenotransplantation. In: Xenograft 25. Hardy MA (ed). Amsterdam, Elsevier, 1989: p. 259Google Scholar
  58. 58.
    Hassan R, Van den Bogaerde JB, Wallwork J, White DJG. Evidence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production. Transplantation 1992; 54: 408CrossRefGoogle Scholar
  59. 59.
    Hoffmann GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • E. Cozzi
  • N. Yannoutsos
  • G. A. Langford
  • G. Pino-Chavez
  • J. Wallwork
  • D. J. G. White

There are no affiliations available

Personalised recommendations